CD441/CD1331 immunophenotype and matrix metalloproteinase-9: Influence on prognosis in early-stage oral squamous cell carcinoma

Head and Neck

Volumn 36, Issue 12, 2014, Pages 1718-1726

  Oliveira, Lucinei R ^a   Castilho Fernandes, Andrielle ^b   Oliveira Costa, Joao Paulo ^b   Soares, Fernando A ^c   Zucoloto, Sergio ^b   Ribeiro Silva, Alfredo ^b  

^a Universidade Vale do Rio Verde   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Cancer stem cells; CD133; CD44; Matrix metalloproteinase 9 (MMP 9); Oral cancer

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; CD133 ANTIGEN; GELATINASE B; HERMES ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HARD PALATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LOWER LIP; MAJOR CLINICAL STUDY; MALE; MOUTH; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; SMOKING; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TOBACCO CONSUMPTION; TONGUE; AGED; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PEPTIDES; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 84912021044     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23527     Document Type: Article

References (65)

1. Sargeran K, Murtomaa H, Safavi SM, Vehkalahti MM, Teronen O. Survival after diagnosis of cancer of the oral cavity. Br J Oral Maxillofac Surg 2008;46: 187-191.
2. Massano J, Regateiro FS, Januario G, Ferreira A. Oral squamous cell carcinoma: Review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102: 67-76.
3. Oliveira LR, Oliveira-Costa JP, Araujo IM, et al. Cancer stem cell immunophenotypes in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40: 135-142.
4. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104: 973-978.
5. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23: 675-699.
6. Graziano A, d'Aquino R, Tirino V, Desiderio V, Rossi A, Pirozzi G. The stem cell hypothesis in head and neck cancer. J Cell Biochem 2008;103: 408-412.
7. Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2007;36: 594-603.
8. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18: 260-267.
9. Richard V, Pillai MR. The stem cell code in oral epithelial tumorigenesis: 'the cancer stem cell shift hypothesis'. Biochim Biophys Acta 2010;1806: 146-162.
10. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4: 33-45.
11. Joshua B, Kaplan MJ, Doweck I, et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: Correlation with tumor aggressiveness. Head Neck 2012;34: 42-49.
12. Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol 1997;50: 57-71.
13. Mizrak D, Brittan M, Alison M. CD133: Molecule of the moment. J Pathol 2008;214: 3-9.
14. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432: 396-401.
15. Gambelli F, Sasdelli F, Manini I, et al. Identification of cancer stem cells from human glioblastomas: Growth and differentiation capabilities and CD133/prominin-1 expression. Cell Biol Int 2012;36: 29-38.
16. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008;14: 4085-4095.
17. Felthaus O, Ettl T, Gosau M, et al. Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines. Biochem Biophys Res Commun 2011;407: 28-33.
18. Curley MD, Therrien VA, Cummings CL, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009;27: 2875-2883.
19. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445: 111-115.
20. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445: 106-110.
21. Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD. A subpopulation of CD133(1) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 2010;289: 151-160.
22. Waldron NN, Kaufman DS, Oh S, et al. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol Cancer Ther 2011; 10: 1829-1838.
23. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2: 161-174.
24. Mashhadiabbas F, Mahjour F, Mahjour SB, Fereidooni F, Hosseini FS. The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114: 240-250.
25. Souza Freitas V, de Andrade Santos PP, de Almeida Freitas R, Pereira Pinto L, de Souza LB. Mast cells and matrix metalloproteinase 9 expression in actinic cheilitis and lip squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112: 342-348.
26. Thanakit V, Sampatanukul P, Ruangvejvorachai P, Keelawat S. The association of co-expression of CD44v4/MMP-9 with different nodal status in high-grade breast carcinoma patients. J Med Assoc Thai 2005;88 Suppl 4: S30-S35.
27. Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92- kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000;17: 1099-1105.
28. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: A potential marker for prognosis. Clin Cancer Res 2004;10: 3110-3116.
29. Ondruschka C, Buhtz P, Motsch C, et al. Prognostic value of MMP-2, -9 and TIMP-1, -2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract 2002;198: 509-515.
30. World Health Organisation International Classification of Dieases-10. International statistical classification of diseases and related health problems. 10th revision. Geneva, Switzerland: World Health Organisation; 1997.
31. Oliveira LR, Ribeiro-Silva A, Costa JP, Sim~oes AL, Matteo MA, Zucoloto S. Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106: 685-695.
32. Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH. Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insights and definitions. Head Neck 2002;24: 198-206.
33. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I, editors. World Health Organisation. International histological classification of tumors: Histological typing of cancer and precancer of the oral mucosa. 2nd ed. Berlin/Heidelberg, Germany: Springer; 1997.
34. Greene FL, Page DL, Fleming ID, editors. AJCC Cancer Staging Manual. 6th ed. New York, New York: Springer-Verlag; 2002.
35. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10: 7621-7628.
36. Simionescu C, Margaritescu C, Surpateanu M, et al. The study of Ecadherine and CD44 immunoexpression in oral squamous cell carcinoma. Rom J Morphol Embryol 2008;49: 189-193.
37. Li CY, Li BX, Liang Y, et al. Higher percentage of CD1331 cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009;7: 56.
38. Sarini J, Fournier C, Lefebvre JL, Bonafos G, Van JT, Coche-Dequeant B. Head and neck squamous cell carcinoma in elderly patients: A long-term retrospective review of 273 cases. Arch Otolaryngol Head Neck Surg 2001; 127: 1089-1092.
39. Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2007;36: 594-603.
40. Harper LJ, Costea DE, Gammon L, Fazil B, Biddle A, Mackenzie IC. Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer 2010;10: 166.
41. Ord RA. Discussion. Primary oral squamous cell carcinoma: A review of 92 cases. J Oral Maxillofac Surg 1996;54: 955.
42. Lindquist D, Ahrlund-Richter A, Tarjan M, Tot T, Dalianis T. Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res 2012;32: 153-161.
43. Kreppel M, Drebber U, Rothamel D, et al. Prognostic impact of different TNM-based stage groupings for oral squamous cell carcinoma. Head Neck 2011;33: 1467-1475.
44. de Aguiar A Jr, Kowalski LP, de Almeida OP. Clinicopathological and immunohistochemical evaluation of oral squamous cell carcinoma in patients with early local recurrence. Oral Oncol 2007;43: 593-601.
45. Freier K, Engel M, Lindel K, et al. Neoadjuvant concurrent radiochemotherapy followed by surgery in advanced oral squamous cell carcinoma (OSCC): A retrospective analysis of 207 patients. Oral Oncol 2008;44: 116-123.
46. Layland MK, Sessions DG, Lenox J. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N1. Laryngoscope 2005;115: 629-639.
47. Ravindran G, Devaraj H. Aberrant expression of CD133 and musashi-1 in preneoplastic and neoplastic human oral squamous epithelium and their correlation with clinicopathological factors. Head Neck 2012;34: 1129-1135.
48. Kosunen A, Pirinen R, Ropponen K, et al. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol 2007;43: 51-59.
49. Masuda M, Kuratomi Y, Shiratsuchi H, Nakashima T, Naonobu K, Komiyama S. Decreased CD44H expression in early-stage tongue carcinoma associates with late nodal metastases following interstitial brachytherapy. Head Neck 2000;22: 662-665.
50. Carinci F, Stabellini G, Calvitti M, et al. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg 2002;13: 85-89.
51. de Jong MC, Pramana J, van der Wal JE, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010; 16: 5329-5338.
52. Okamoto A, Chikamatsu K, Sakakura K, Hatsushika K, Takahashi G, Masuyama K. Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol 2009;45: 633-639.
53. Chikamatsu K, Ishii H, Takahashi G, et al. Resistance to apoptosisinducing stimuli in CD441 head and neck squamous cell carcinoma cells. Head Neck 2012;34: 336-343.
54. Margaritescu C, Pirici D, Simionescu C, Stepan A. The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC). Rom J Morphol Embryol 2011;52(3 Suppl): 985-993.
55. Wang SJ, Wreesmann VB, Bourguignon LY. Association of CD44 V3- containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck 2007;29: 550-558.
56. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009;119: 1518-1530.
57. Bankfalvi A, Krassort M, Buchwalow IB, Vegh A, Felszeghy E, Piffko J. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol 2002; 198: 343-351.
58. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. Blood 1997;90: 5013-5021.
59. Mascolo M, Ilardi G, Romano MF, et al. Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer. Histopathology 2012;61: 1089-1105.
60. Sun Y, Han J, Lu Y, Yang X, Fan M. Biological characteristics of a cell subpopulation in tongue squamous cell carcinoma. Oral Dis 2012;18: 169-177.
61. Benassi MS, Gamberi G, Magagnoli G, et al. Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol 2001;12: 75-80.
62. van Kempen LC, Coussens LM. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002;2: 251-252.
63. Juarez J, Clayman G, Nakajima M, et al. Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in 2 invasive squamous-cellcarcinoma cell lines of the oral cavity. Int J Cancer 1993;55: 10-18.
64. Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol 2000;36: 207-213.
65. Zhou X, Temam S, Oh M, et al. Global expression-based classification of lymph node metastasis and extracapsular spread of oral tongue squamous cell carcinoma. Neoplasia 2006;8: 925-932.